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MERS-CoV Antibody Responses 1 Year after Symptom 
Onset, South Korea, 2015 
Technical Appendix 
Methods 
The plaque-reduction neutralization test (PRNT) was performed in duplicate in a biosafety level 3 facility by using 24-well 
tissue culture plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland). Serial dilutions of serum samples were incubated 
with 50–70 plaque-forming units of virus for 1 h at 37°C. The virus-serum mixtures were added on to Vero cell monolayers and 
incubated 1 h at 37°C in 5% CO2 incubator. Then the plates were overlaid with 1% agarose in cell culture medium and incubated for 3 
days when the plates were fixed and stained. Antibody titers were defined as the highest serum dilution that resulted in >90% 
(PRNT90) reduction in the number of plaques (1). 
For the microneutralization assay, 2-fold dilutions of serum samples were incubated with an equal volume of 200 tissue culture 
infectious dose 50s of Middle East respiratory syndrome coronavirus (MERS-CoV) (2). After 1 h incubation at 37°C, the virus-serum 
mixture was added in quadruplicate to preformed Vero cell monolayers in 96-well microtiter plates (TPP Techno Plastic Products 
AG). Cytopathic effect was observed at 3 days postinfection. The highest serum dilution that completely protected the cells from 
cytopathic effect in >2 of the 4 wells was taken as the neutralizing titer. Virus back titrations were carried out in each assay to confirm 
that the virus challenge dose was within expected range. 
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The virus pseudoparticle neutralization test (ppNT) was performed as previously described (2). Lentivirus pseudoparticles 
containing codon optimized MERS-CoV (EMC strain) spike protein and a luciferase reporter gene were incubated with serially 
diluted serum samples for 1 h at 4°C and then added to Vero E6 cells (CRL-1586; American Type Culture Collection, Manassas, VA, 
USA) in triplicate. Residual virus replication was assayed by the luciferase counts at 2 days postinfection. The highest serum dilution 
giving a 90% reduction of luciferase activity was regarded as the ppNT antibody titer. 
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Technical Appendix Table 1. Characteristics and PRNT90 titers of the patients from the MERS-CoV outbreak, South Korea, 2015* 
Patient 
Sex/age, 
y Underlying disease 
CXR 
infiltrates 
Oxygen 
therapy 
Mechanical 
ventilation 
Corticosteroid 
therapy 
Antiviral 
use 
Outcome (day post 
disease onset) 
Included in 
present study 
PRNT90 antibody titer 21–
50 days post disease onset 
A M/38 – Yes Yes Yes Yes Yes Transfer (61) No 80 
B M/65 – Yes Yes Yes Yes Yes Died  (142) No >320 
C M/55 – Yes Yes Yes No Yes Discharge (26) Yes 640 
D M/35 Bacterial pneumonia Yes Yes Yes Yes Yes Discharge (33) Yes 160 
E F/79 CHD, dementia, CKD, bladder 
cancer 
Yes Yes Yes Yes Yes Died (17) No NA (<10 on day 16) 
F M/55 DM, COPD, lung abscess Yes Yes No Yes No Discharge (31) Yes 320 
G M/56 – Yes Yes No No Yes Discharge (40) Yes 80 
H M/71 DM, CVA, aspiration pneumonia Yes Yes No No No Discharge (38) No 160 
I F/77 DM, asthma Yes Yes No No No Discharge (18) Yes NA (40 on day 18) 
J M/76 DM, CHD Yes No No No No Discharge (28) No 40 
K M/59 CHD Yes No No No Yes Discharge (19) Yes 80 
L F/56 – Yes No No No No Discharge (21) Yes <10 
M M/56 DM, CHD, CLD, TB Yes No No No No Discharge (16) Yes NA (<10 on day 16) 
N F/54 – Yes No No No No Discharge (21) Yes 80 
O M/46 – Yes No No No No Discharge (12) Yes NA 
P M/35 – No No No No Yes Discharge (14) Yes 10 
Q M/52 DM, liver abscess Yes No No No Yes Discharge (21) No 160 
*CHD, coronary heart disease; CKD, chronic kidney disease; CLD, chronic lung disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CXR, chest 
X-ray; DM, diabetes mellitus; NA, not applicable; PRNT90, >90% plaque-reduction neutralization test; TB, tuberculosis. 
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Technical Appendix Table 2. MERS-CoV antibody titers in patient serum samples* 
Patient ID 
Day serum collected after 
disease onset 
Reciprocal MERS-CoV MN antibody titer 
MERS-CoV EMC MERS-CoV Hu/KOR/SNU1_035/2015 
F 58 80 160 
F 403 40 40 
M 16 <10 <10 
M 394 <10 <10 
L 99 <10 <10 
L 403 <10 <10 
O 8 <10 <10 
O 379 <10 <10 
I 18 20 40 
I 298 20 40 
*Patient titers were assessed with prototype strain EMC and a virus isolate Hu/KOR/SNU1_035/2015 from the outbreak in South 
Korea in 2015. ID, identification; MERS-CoV, Middle East respiratory syndrome coronavirus; MN, microneutralization. 
 
Technical Appendix Table 3. Spearman correlation between peak viral loads in the acute phase of illness and serologic responses at different time points post disease onset* 
Time post disease onset 
PRNT90  ELISA OD ratio 
Spearman correlation p value  Spearman correlation p value 
Acute phase† 0.20 0.56  0.13 0.71 
≈6 mo 0.17 0.64  0.45 0.19 
≈1 y 0.17 0.62  0.37 0.26 
*Peak viral load (log10 UpE virus RNA copies/mL) was measured in sputum. All correlations were not statistically significant and changed by <0.1 with 
imputed values from nearest testing occasions. OD, optical density; PRNT90, >90% plaque-reduction neutralization test; upE, region upstream of the 
E gene. 
†Peak antibody titer during the acute phase was used in these analyses. 
 
Technical Appendix Table 4. Spearman correlation between durations of viral shedding and serologic responses at different time points post disease onset* 
Time post disease onset 
PRNT90  ELISA OD ratio 
Spearman correlation p value  Spearman correlation p value 
Acute phase† 0.74 0.010  0.77 0.006 
≈6 mo 0.74 0.015  0.79 0.007 
≈1 y 0.79 0.004  0.80 0.003 
*All correlations were statistically significant and changed by <0.06 with imputed values from nearest testing occasions. OD, optical density; PRNT90, 
>90% plaque-reduction neutralization test. 
†Peak antibody titer during the acute phase was used in these analyses. 
 
